SHORT-TERM ECONOMIC AND CLINICAL OUTCOMES OF CANAGLIFLOZIN COMPARED TO SITAGLIPTIN IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS (T2DM)

被引：0
|
作者：
Lopez, J. M. [1 ]
Martin, S. [1 ]
Ektare, V [2 ]
Patel, D. [3 ]
Rupnow, M. F. [1 ]
Botteman, M. F. [2 ]
机构：
[1] Janssen Sci Affairs LLC, Raritan, NJ USA
[2] Pharmerit Int, Bethesda, MD USA
[3] Pharmerit North Amer LLC, Bethesda, MD USA
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 03期
关键词：
D O I：
10.1016/j.jval.2014.03.1463
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB77
引用
收藏
页码：A251 / A251
页数：1
相关论文
共 50 条
  • [1] Short-term outcomes of patients with Type 2 diabetes mellitus treated with canagliflozin compared with sitagliptin in a real-world setting
    Shao, Yan Li
    Yee, Kuan Hao
    Koh, Seow Ken
    Wong, Yip Fong
    Yeoh, Lee Ying
    Low, Serena
    Sum, Chee Fang
    [J]. SINGAPORE MEDICAL JOURNAL, 2018, 59 (05) : 251 - 256
  • [2] IS CANAGLIFLOZIN COST-EFFECTIVE COMPARED TO SITAGLIPTIN ACROSS MULTIPLE LINES OF TYPE 2 DIABETES MELLITUS (T2DM) THERAPY IN IRELAND?
    Bacon, T.
    Willis, M.
    Johansen, P.
    Neslusan, C.
    Nuhoho, S.
    Worbes-Cerezo, M.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A345 - A345
  • [3] Canagliflozin (CANA) Compared With Sitagliptin (SITA) in Subjects With Type 2 Diabetes Mellitus (T2DM) on Metformin (MET) Over 52 Weeks
    Lavalle Gonzalez, Fernando J.
    Januszewicz, Andrzej
    Davidson, Jaime
    Qiu, Rose
    Tong, Cindy
    Meininger, Gary
    [J]. DIABETES, 2013, 62 : A61 - A61
  • [4] COST-EFFECTIVENESS OF SAXAGLIPTIN COMPARED TO SITAGLIPTIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
    Hutchings, A.
    Tolley, K.
    Achana, F.
    Brereton, N. J.
    Lebmeier, M.
    Mesa, O. A.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A478 - A478
  • [5] Characteristics of Patients with Type 2 Diabetes Mellitus (T2DM) Initiating Therapy with Canagliflozin
    Martin, Silas C.
    Henk, Henry J.
    Chow, Wing
    [J]. DIABETES, 2014, 63 : A307 - A307
  • [6] Pregnancy outcomes in women with Type 2 diabetes mellitus (T2DM)
    Tan, Z.
    Pang, W. H.
    Todd, D.
    Halliday, M.
    Gill, F.
    Rhoads, M.
    Sathiskumar, P.
    Gallagher, A.
    de Chazal, R.
    Lawrence, I. G.
    [J]. DIABETIC MEDICINE, 2008, 25
  • [7] Genital Mycotic Infections With Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM)
    Nyirjesy, Paul
    Sobel, Jack
    Fung, Albert
    Gassmann-Mayer, Cristiana
    Ways, Kirk
    Usiskin, Keith
    [J]. DIABETES, 2013, 62 : A276 - A276
  • [8] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN VERSUS SITAGLIPTIN AS THIRD-LINE THERAPY IN TYPE 2 DIABETES MELLITUS (T2DM) IN A CANADIAN SETTING
    Sabapathy, S.
    Neslusan, C.
    Yoong, K.
    Teschemaker, A. R.
    Johansen, P.
    Willis, M.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A61 - A61
  • [9] Lower Blood Pressure (BP) With Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM)
    Weir, Matthew R.
    Januszewicz, Andrzej
    Gilbert, Richard
    Gonzalez, Fernando Lavalle
    Meininger, Gary
    [J]. DIABETES, 2013, 62 : A278 - A278
  • [10] Urinary Tract Infection (UTI) With Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM)
    Nicolle, Lindsay E.
    Capuano, George
    Fung, Albert
    Usiskin, Keith
    [J]. DIABETES, 2013, 62 : A296 - A296
12345